As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Shtanko, Olena
Funded by
National Institutes of Health
Collaborating Institutions
University of Iowa
The major goal of this project is to elucidate the role of virus-induced events in CD40 signaling in macrophages and the importance of these signals for controlling filovirus infection. Work will use both existing and new virus stocks to challenge the selected tissues and include infection assays, cytokine/chemokine profiling, virus inactivation, analysis of infection efficiencies, and mice virus challenge.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Torrelles, Jordi B
To determine the efficiency of a novel agar-layer based test for the diagnosis of drug resistant tuberculosis in Mozambique
BioBridge Global is a San Antonio, Texas-based nonprofit corporation that offers diverse services through its subsidiaries – the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure and the Blood & Tissue Center Foundation.
Principal Investigator(s)
Jack Hager
Collaborating Institutions
Abbott
QualTex Laboratories, a subsidiary of San Antonio-based nonprofit BioBridge Global, has begun testing blood and plasma donations on its second automated track system, expanding its capabilities in its San Antonio laboratory.
BioBridge Global is a San Antonio, Texas-based nonprofit corporation that offers diverse services through its subsidiaries – the South Texas Blood & Tissue Center, QualTex Laboratories, GenCure and the Blood & Tissue Center Foundation.
Collaborating Institutions
Trauma Hemostasis & Oxygenation Research,
U.S. Army Institute of Surgical Research,
Mayo Clinic,
Terumo BCT
The U.S. Food and Drug Administration has granted the South Texas Blood & Tissue Center (STBTC) approval to manufacture and distribute cold-stored platelets with a shelf life of 14 days for the treatment of actively bleeding patients when conventional platelets are not available, or their use is not practical.
Platelets are a key blood component constantly in demand for treating severe bleeding, for example in trauma and maternal hemorrhage patients.
Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Principal Investigator(s)
Dr. Shawn Blumberg
Funded by
SwRI internal funding
Collaborating Institutions
Texas Biomedical Research Institute
Drug discovery software at Southwest Research Institute is expanding the capacity to virtually screen drug compounds for possible treatment of coronavirus and other infectious diseases.
SwRI’s Rhodium™ virtual screening tool recently evaluated 2 million drug compounds in a few days, hoping to identify high-probability drugs that may have efficacy against the coronavirus with minimal adverse side effects. Institute scientists initiated the molecular modeling research with SwRI internal funding.
Southwest Research Institute (SwRI), headquartered in San Antonio, Texas, is one of the oldest and largest independent, nonprofit, applied research and development (R&D) organizations in the United States.
Principal Investigator(s)
Dr. Joe McDonough
Funded by
San Antonio Partnership for Precision Therapeutics
Collaborating Institutions
The University of Texas at San Antonio
UT Health San Antonio
Texas Biomedical Research Institute
Leaders of the newly-established San Antonio Partnership for Precision Therapeutics (SA PPT) have awarded the partnership’s first research grant. A seven-person team researching sepsis-induced organ failure will receive $200,000 in funding over two years. The award’s purpose is to advance research and breakthroughs in precision therapeutics, which is the development of drug therapies for specific populations based on genetics, lifestyle and environment.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Martinez-Sobrido, Luis
Funded by
National Institutes of Health
Collaborating Institutions
University of Alabama
The extensive genetic variability in seasonal and potentially pandemic influenza strains necessitates new vaccine strategies that can focus the immune response on generating protective antibodies against conserved targets such as regions within the influenza neuraminidase protein. We have demonstrated that seasonal immunization stimulates neuraminidase specific antibodies in humans that are broad and potent in their protection from influenza when tested in animals.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Martinez-Sobrido, Luis
Funded by
Department of Defense
Collaborating Institutions
University of Rochester
This project will characterize the safety, immunogenicity and protective efficacy of selected rLCMV/ts in mice.This contract involves virulence, immunogenecity and protective efficacy studies.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Carrion, Ricardo
Funded by
Biomedical Advanced Research and Development Authority
Collaborating Institutions
Mapp Biopharmaceutical
Inc.
The Major goal is to test efficacy of novel monoclonal therapeutic in the Sudan virus NHP Model.
As one of the world’s leading independent biomedical research institutions, Texas Biomedical Research Institute is dedicated to advancing the health of our global community through innovative biomedical research.
Principal Investigator(s)
Martinez-Sobrido, Luis
Funded by
National Institutes of Health
Collaborating Institutions
University of Rochester
We will test the hypothesis that neonatal hyperoxia enhances sensitivity to IAV infection by inducing epigenetic changes in proliferating AEC2s that are maintained even when they become AEC1s and these changes are mediated by the persistent expression of Ki67. Understanding how neonatal hyperoxia shapes how AECs respond to IAV infection is important because the scientific discoveries will stimulate development of novel therapies designed to improve the health of people born preterm.